Literature DB >> 26457331

Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.

Terry R Medler1, Tiziana Cotechini1, Lisa M Coussens2.   

Abstract

Chemotherapy and radiotherapy have been extensively used to eradicate cancer based on their direct cytocidal effects on rapidly proliferating tumor cells. Accumulating evidence indicates that these therapies also dramatically affect resident and recruited immune cells that actively support tumor growth. We now appreciate that mobilization of effector CD8+ T cells enhances efficacy of chemotherapy and radiotherapy; remarkable clinical advances have been achieved by blocking regulatory programs limiting cytotoxic CD8+ T cell activity . This review discusses immune-mediated mechanisms underlying efficacy of chemotherapy and radiotherapy, and provides a perspective on how understanding tissue-based immune mechanisms can be used to guide therapeutic approaches combining immune and cytotoxic therapies to improve outcomes for a larger subset of patients than currently achievable.

Entities:  

Keywords:  Checkpoints; Chemotherapy; Immunosuppression; Macrophage; Radiotherapy

Year:  2015        PMID: 26457331      PMCID: PMC4594836          DOI: 10.1016/j.trecan.2015.07.008

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  110 in total

Review 1.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 2.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.

Authors:  Stephen L Shiao; Brian Ruffell; David G DeNardo; Bruce A Faddegon; Catherine C Park; Lisa M Coussens
Journal:  Cancer Immunol Res       Date:  2015-02-25       Impact factor: 11.151

Review 5.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

6.  IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.

Authors:  Vasilena Gocheva; Hao-Wei Wang; Bedrick B Gadea; Tanaya Shree; Karen E Hunter; Alfred L Garfall; Tara Berman; Johanna A Joyce
Journal:  Genes Dev       Date:  2010-01-15       Impact factor: 11.361

7.  Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.

Authors:  Edward P Chen; Nune Markosyan; Emma Connolly; John A Lawson; Xuanwen Li; Gregory R Grant; Tilo Grosser; Garret A FitzGerald; Emer M Smyth
Journal:  Carcinogenesis       Date:  2014-03-03       Impact factor: 4.944

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer.

Authors:  H F Sewell; C F Halbert; R A Robins; A Galvin; S Chan; R W Blamey
Journal:  Int J Cancer       Date:  1993-11-11       Impact factor: 7.396

10.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Authors:  Debbie C Strachan; Brian Ruffell; Yoko Oei; Mina J Bissell; Lisa M Coussens; Nancy Pryer; Dylan Daniel
Journal:  Oncoimmunology       Date:  2013-12-04       Impact factor: 8.110

View more
  35 in total

Review 1.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

Review 2.  Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Authors:  Theodore S Johnson; Tracy Mcgaha; David H Munn
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 3.  Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.

Authors:  Yu Lei; Yuying Xie; Yee Sun Tan; Mark E Prince; Jeffrey S Moyer; Jacques Nör; Gregory T Wolf
Journal:  Oral Oncol       Date:  2016-08-21       Impact factor: 5.337

4.  Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11).

Authors:  Sridharan Gururangan; Elizabeth Reap; Robert Schmittling; Mehmet Kocak; Renee Reynolds; Gerald Grant; Arzu Onar-Thomas; Patricia Baxter; Ian F Pollack; Peter Phillips; James Boyett; Maryam Fouladi; Duane Mitchell
Journal:  Cancer Immunol Immunother       Date:  2017-08-20       Impact factor: 6.968

Review 5.  IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.

Authors:  David H Munn; Madhav D Sharma; Theodore S Johnson; Paulo Rodriguez
Journal:  Cancer Immunol Immunother       Date:  2017-05-09       Impact factor: 6.968

Review 6.  Homeostasis Back and Forth: An Ecoevolutionary Perspective of Cancer.

Authors:  David Basanta; Alexander R A Anderson
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

7.  Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.

Authors:  Irena Kaplanov; Yaron Carmi; Rachel Kornetsky; Avishai Shemesh; Galina V Shurin; Michael R Shurin; Charles A Dinarello; Elena Voronov; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-13       Impact factor: 11.205

8.  Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx.

Authors:  Ankur Chakravarthy; Stephen Henderson; Stephen M Thirdborough; Christian H Ottensmeier; Xiaoping Su; Matt Lechner; Andrew Feber; Gareth J Thomas; Tim R Fenton
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 9.  Current challenges for cancer vaccine adjuvant development.

Authors:  William S Bowen; Abhishek K Svrivastava; Lalit Batra; Hampartsoum Barsoumian; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2018-02-08       Impact factor: 5.217

Review 10.  Therapy-induced microenvironmental changes in cancer.

Authors:  Yuting Ma; Heng Yang; Jonathan M Pitt; Guido Kroemer; Laurence Zitvogel
Journal:  J Mol Med (Berl)       Date:  2016-03-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.